Healthcare

Eli Lilly opposes using imports to tackle high drug prices

By Robert King
Published July 24, 2018 2:27pm ET
Add Washington Examiner on Google
Eli Lilly opposes using imports to tackle high drug prices
FILE - In this file photo taken Thursday, Feb. 9, 2012, a pharmacist is seen working in a lab where medicines are being produced at a manufacturing unit on the outskirts of Mumbai, India. India's patent office on Monday march 12, 2012 effectively ended Bayer's monopoly on a patented cancer drug by allowing the manufacturing of a generic copy at a fraction of the price. | (AP Photo/Rafiq Maqbool, File)

Major drug maker Eli Lilly denounced imports from overseas to provide competition for extremely high-priced drugs.

Lilly’s comments on Tuesday during an earnings call comes nearly a week after the Trump administration said it plans to examine using foreign imports to fight high prices. Lilly said the method itself was concerning.

Already a print subscriber? Click here to login/register your account

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.

Tag:

Alex Azar Medicare and Medicaid Pharmaceutical Industry